Alphabet Replaces Verizon in Dow Jones Industrial Average 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
LEXINGTON, Mass., Feb. 17, 2016 -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that the Company will present at the 2016 RBC Capital Markets Global Healthcare Conference on February 24, 2016, at 11:00 a.m. Eastern Time in New York City.
The presentation will be held using a fireside-chat format in which Dr. Ali Fattaey, President and Chief Executive Officer, will provide a brief overview of the Company’s pipeline of drug candidates and business strategy, after which an equity analyst will moderate a question and answer session.
A corresponding webcast of the presentation can be accessed by visiting:
http://www.veracast.com/webcasts/rbc/healthcare2016/88207347337.cfm
The webcast will be archived shortly after the live event and available for 30 days following the conference, and also available for 30 days on the Investor Relations section of the Curis website at www.curis.com.
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, a dual HDAC and PI3K inhibitor that is being investigated in two clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD-1 pathway/ VISTA, including PD-L1/VISTA antagonist CA-170, as well as to molecules designed to inhibit IRAK4, including CA-4948. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.
For more information, visit Curis' website at www.curis.com.
For More Information: Mani Mohindru, Ph.D. Senior Vice President, Corporate Strategy and Investor Relations Curis, Inc. 617-503-6605 [email protected] Media Contact David Schull Russo Partners (212) 845-4271 [email protected]
